chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Passed out right after vaccine; muscle aches; tired; chills; migraine; This is a spontaneous report from a non-contactable consumer (patient). A 17-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in the left arm on 14Apr2021 at 14:15 (Batch/Lot number was not reported) as single dose for covid-19 immunization, administered at the Pharmacy or Drug store. The patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 17Mar2021 at 14:15 in the left arm for covid-19 immunisation. The patient's medical history was not reported. There were no concomitant medications. The patient was not pregnant at the time of report and vaccination. The patient did not receive other vaccines in four weeks. The patient had no COVID prior to vaccination and was not tested for COVID post vaccination. The patient passed out right after vaccine, also experienced muscle aches, tired, chills, and migraine; all on 14Apr2021 with outcome of unknown.  No follow-up attempts are possible, information about batch number cannot be obtained. No further information is expected.
CUP SIZED RASH ON ARM BELOW SITE OF ADMINISTRATION. RASH HAS SWELLING AND ERYTHEMA, AND FEELS WARM TO COMPRESS.
red, warm, swollen arm about the size of a tennis ball. Painful to the touch or move.  Patient reported feeling sick also. Patient treated with a few doses of advil and warm compresses. by 10/6/2020 patient reports increased mobility (able to raise arm straight over shoulder, and just a little soreness left).  Patient was visiting a doctor for unrelated  other arm issue the next day and was advised to take some more advil and consult md to see if a steroid would be appropriate to help reduce inflammation.
Injection site red, warm to touch, swollen, itchy. Symptoms worsened on 09/10/15. Thigh checked 9/10/15, redness spreading, injection site harder to touch. Warm to touch, No fever.
COVID-19 Treatment; COVID-19 Treatment; COVID vaccine details: Moderna Dose 4, Pfizer dose 1,2,3; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 49-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 14Apr2021 as dose 1, single (Lot number: ER8729), in left arm, on 05May2021 as dose 2, single (Lot number: EW0173), in left arm and on 17Nov2021 as dose 3 (booster), single (Lot number: fj8787) at the age of 48 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 06Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa antibiotics" (unspecified if ongoing), notes: Known allergies: Sulfa antibiotics. The patient's concomitant medications were not reported.  The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 06Sep2022, outcome "unknown", described as "COVID vaccine details: Moderna Dose 4, Pfizer dose 1,2,3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Nov2022, outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Nov2022) Positive, notes: Tested positive, again after 3 days of negative tests; (Nov2022) Negative, notes: Tested positive, again after 3 days of negative tests; (Nov2022) Negative, notes: Tested positive, again after 3 days of negative tests; (Nov2022) Negative, notes: Tested positive, again after 3 days of negative tests. Therapeutic measures were taken as a result of vaccination failure, covid-19. No follow-up attempts are possible. No further information is expected.
Vaccine was administered after 12 hours of first puncture. Vaccine given after being at room temperature for 23 hours. Manufacturer of Moderna contacted and they stated that vaccine still effective if done within 24 hours of first puncture. No adverse event reported by patient.
loss of energy; blood sugar dropped; taste of chemical thing; smell of chemical thing; she was tired; Scheduled for second shot on 14Dec2021. But hasn't gotten it yet; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (loss of energy), BLOOD GLUCOSE DECREASED (blood sugar dropped), TASTE DISORDER (taste of chemical thing), PAROSMIA (smell of chemical thing) and FATIGUE (she was tired) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 065F21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 (She experienced a chemical smell or taste at the time.) in August 2021.    On 16-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (loss of energy), BLOOD GLUCOSE DECREASED (blood sugar dropped), TASTE DISORDER (taste of chemical thing), PAROSMIA (smell of chemical thing), FATIGUE (she was tired) and PRODUCT DOSE OMISSION ISSUE (Scheduled for second shot on 14Dec2021. But hasn't gotten it yet). At the time of the report, ASTHENIA (loss of energy), BLOOD GLUCOSE DECREASED (blood sugar dropped) and FATIGUE (she was tired) had resolved, TASTE DISORDER (taste of chemical thing) and PAROSMIA (smell of chemical thing) had not resolved and PRODUCT DOSE OMISSION ISSUE (Scheduled for second shot on 14Dec2021. But hasn't gotten it yet) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient is on unspecified blood pressure and cholesterol medications. Patient has not taken second dose of vaccine which was scheduled on 14-Dec-2021. The patient did not take any treatment medications.
8 days after smallpox vaccination, pt noticed vax site red, inflamed, local pain, mild swelling. 11 days after, maculopapular and pustular lesions formed on full body, scattered, no itching. Pain on the ones in the upper extremities.
Expired Vaccine given, Vaccine expired 6/1/22, given 6/22/22
This spontaneous report was received from a pharmacist concerning a 67 year old female patient. On 09-SEP-2014 the patient was vaccinated with a dose of ZOSTAVAX vial 19400 PFU (Lot number not provided), 0.65 ml, subcutaneous. The pharmacist reported that as the patient was leaving the store on 09-SEP-2014, the injection site started itching intensely. She stated that the patient reported that the injection site was hot to the touch, raised, and sore, and that the patient had been fatigued since she received the dose on 09-SEP-2014. No treatment was given for the patient's adverse events. There were no laboratory tests or diagnostic studies performed. At the time of the report, the patient had not recovered. Additional information has been requested.
third dose of Shingrix was administrated; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 58-year-old male patient who received Herpes zoster (Shingrix) (batch number z4427, expiry date 31st January 2023) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date) and Shingrix (received 2nd dose in February 2021).   On 4th October 2021, the patient received the 3rd dose of Shingrix. On 4th October 2021, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.  Additional details provided were as follows: The pharmacist report that a third dose of Shingrix was administrated by error, which led to extra dose administered. The reporter stated the patient came and claimed that he had not received that dose and due to miscommunication between colleagues and the patient did not notified that they had received already a second dose and the health care professional administrated a third dose thinking it was the second dose the patient would be receiving. The third dose was not administrated on the same day as the second dose. No further events were reported. The reporter agreed to be contacted for follow-up.
redness and swelling about 2 and 1/2 inches below injection site (described as 3 inches long, 2 inches wide); patient currently applying ice pack
Caller stated the patient has not reported any symptoms; Nurse called to report that a 6 year old patient received a dose of PEDVAXHIB on 8/25/2023. Caller stated the patient had received previous doses of PEDVAXHIB on 9/8/2017, 11/8/2017, 1/9/2018, and 10/15/2018.; Nurse called to report that a 6 year old patient received a dose of PEDVAXHIB on 8/25/2023; Previous dose on 10/15/2018; Previous dose on 1/9/2018; This spontaneous report was received from a registered nurse and refers to a 6-month-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 08-SEP-2017, the patient was vaccinated with Haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) intramuscular injection, administered for prophylaxis (dose, frequency, strength, lot #, expiry date, and route of administration were not provided). Later, on 08-NOV-2017, 09-JAN-2018 (Inappropriate schedule of product administration), and 15-OCT-2018 (Extra dose administered), he received additional doses of the vaccine. Then, on 25-AUG-2023, when patient had 6 years, a dose of Haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) was given (Product administered to patient of inappropriate age) (Extra dose administered). The patient had no reported any symptoms (No adverse event).
Information has been received from a LPN concerning a 28 day old female who on 09-MAR-2001 at 10:45 AM, the pt received a first dose in the right thigh of Comvax. Concomitant vaccine therapy that day included a first dose in the right thigh of Prevnar and a first dose in the left thigh of ACEL-IMMUNE. At the time of this report, the pt had no adverse symptoms. Unspecified medical attention was sought. Follow up information received from the physician's office indicated that the pt's mother reported the pt ran a temperature and had local reactions (swelling, limp) following the vaccinations. No further details provided. Additional information has been requested.
Initial report received from a nurse on 01 November 2013. A female patient, whose age, medical history and concomitant medications were not reported, had received a dose of FLUZONE (Lot number UH894AA, route and site of vaccination were not reported), on 30 October 2013. On 30 October 2013, after receiving vaccine the patient experienced headache, no appetite, nausea, and stomach cramping. At the time of this report the outcome of adverse events were not recovered. Documents held by sender: none.
Patient here for 2nd dose of covid vaccine and was inadvertantly given Moderna.  First dose was Pfizer Lot # EP7533, given on 04/16/2021.
pain in his lower back; pain in his knee is "killing him"; fever of 103° F; if he gets up, he has extreme neck pain: "It's killing me"; pain in the arm; This spontaneous case was reported by a consumer and describes the occurrence of NECK PAIN (if he gets up, he has extreme neck pain: "It's killing me"), PAIN IN EXTREMITY (pain in the arm), BACK PAIN (pain in his lower back), ARTHRALGIA (pain in his knee is "killing him") and PYREXIA (fever of 103° F) in a 29-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020F21A and 052E21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in March 2021 and Pneumonia in March 2021.   On 31-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Sep-2021, the patient experienced NECK PAIN (if he gets up, he has extreme neck pain: "It's killing me"), PAIN IN EXTREMITY (pain in the arm), ARTHRALGIA (pain in his knee is "killing him") and PYREXIA (fever of 103° F). On an unknown date, the patient experienced BACK PAIN (pain in his lower back). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, NECK PAIN (if he gets up, he has extreme neck pain: "It's killing me"), PAIN IN EXTREMITY (pain in the arm), BACK PAIN (pain in his lower back), ARTHRALGIA (pain in his knee is "killing him") and PYREXIA (fever of 103° F) outcome was unknown.            No Concomitant informations were reported.   This case was linked to MOD-2021-335720 (Patient Link).   Reporter did not allow further contact
Severe chills and headache for 24 hours, fever for a few hours, hives around injection site and on chest and face
about 15 min. after injection pt. began feeling anxious, tearful, difficulty swallowing, pt. able to drink water, speaking in full sent., no rash, no hives, no itching, voice normal, no audible wheezes noted.  Team alert called and pt. taken to ED for evaluation
Parent stated S/Sx started on the evening of the vaccine. Pt C/o not being able to walk d/t pain in R leg where vaccine given. Screaming in pain today 4/29 and can't walk.  Injection site is painful, no redness, warm to touch, and hard where vaccine was given on R leg.
Reporting a vaccine administration error. An adult dose of the Pfizer COVID-19 vaccine was given to a pediatric patient instead of the pediatric vaccine. No adverse reaction reported.
Lethargic for days after the shots. Fevers off & on for 2 wks after last 2 series of shots. Respiratory symptoms - cough with SOB & diarrhea.
Soon after vaccine, patient complained of feeling lump at injection site and funny taste in mouth. She became light headed and warm. Patient was given cool compress and took a dose of BENADRYL after EMS arrived. Symptoms subsided within 30 minutes.
Hives after 2013-2015 flu vaccination: reported receipt of injectable (IM) flu vaccines in 2013 and 2015 with onset of hives few hours later lasting 1-3 days but has not had reactions with intranasal influenza. Review of past reactions: Flu vaccine by PMC/Sanofi (FLUZONE) Lot # UH899AE was given alone on 31 Oct 2013. She advised onset total body itching with scattered outbreaks of mosquito bite like bumps everywhere and hives. Medic advised use of BENADRYL with resolution of all symptoms within a few days. On 15 Oct 2015 she received CSL Lot U56506 (AFLURIA) and again experienced repeat of 2013 reaction of hives and generalized itching allover. She was evaluated on 19 Oct 2015 (see note) where providers reported 5 day Hx of hives that move about on her legs/hands that were not resolving with BENADRYL. She was treated with IM SOLUMEDROL 125mg, and released with oral CLARITIN and topical steroid creams. Providers documented small papular rash to both thighs with raised welts otherwise normal exam. She advised the reaction resolved within a few days and has not reoccurred. She denied any new food groups, detergents, deodorants, clothing, or any other systemic reactions such as angioedema, difficulty breathing, site reactions, headaches, myalgia, arthralgia, et al with either reaction or prior to/after each reaction. Given flu vaccine (AFLURIA) Lot WT58908 Trivalent flu vaccine 11/18/2016 at allergy clinic with no adverse reaction.
CONFIRMED IMMUNOLOGICAL VACCINATION FAILURE; BODY ACHES ALL OVER THE BODY BUT MAINLY IN THE HIPS; ARM SORENESS; FEELING FEVERISH BUT NOT A REALLY FEVER; This spontaneous report received from a patient concerned a 52 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 042A21A expiry: UNKNOWN) dose was not reported, 1 total, administered on APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, in the evening of the day of vaccination (about 8 hours after vaccination), the patient had body aches all over the body but mainly in the hips, and feeling feverish but not really a fever, and arm soreness (cannot recall which arm) and were gone by 36-48 hours later. On 01-SEP-2021, the patient did an antibody blood test that showed no antibodies to the spike protein of covid-19 (negative antibody test) and developed confirmed immunological vaccination failure. Laboratory data included: COVID-19 antibody test (NR: not provided) showed no antibodies to the spike protein of covid-19. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches all over the body but mainly in the hips, arm soreness, and feeling feverish but not a really fever, and the outcome of confirmed immunological vaccination failure was not reported. This report was serious (Other Medically Important Condition).  This report was associated with RA:90000193687.; Sender's Comments: V0: 20210934232-COVID-19 VACCINE AD26.COV2.S-Confirmed immunological vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS
This spontaneous report as received from a registered nurse refers to a 8 week old patient of unknown gender. The patient's concurrent conditions, medical history and drug allergies were not reported. On 27-OCT-2016, the patient was vaccinated with improperly stored PEDVAXHIB (dose and route not reported) from lot # M020102, expiry date: 08-MAR-2019 for prophylaxis. Concomitant medications were not reported. The patient was vaccinated at a private healthcare center and the vaccine was purchased with Private pay/ Insurance. The vaccine was exposed to a temperature of 34.5 Fahrenheit for 100 minutes. Data logger was involved. There were no previous temperature excursions. No adverse events were reported. Product quality complaint was not involved. This is one of the several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1610USA014705: US-009507513-1610USA014706: US-009507513-1610USA008140.
Patient complains of a rash all over his back and shoulders. Arm pain still lingering. Patient states the vision in left eye is affected.
Patient syncopal after administration of vaccine. No incontinence. No tremors. After rising continues to feel dizzy with poor recall of event - sent by EMS to ED for eval concussion. Abrasion -> chin.
The vaccination was administered on my left shoulder at the rotator cuff or subacromial bursa area. I want to communicate that it was way too high in the shoulder and I experienced loss range of motion in Left shoulder for 5 days. I am feeling better today. Is the vaccination effective if given high in the shoulder?  I have photos of bandaid and area of bruising if that is helpful.   I want to make sure that those giving the vaccination know where to administer.
diarrhea; rash to torso; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea) and RASH (rash to torso) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0269219) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced DIARRHOEA (diarrhea) and RASH (rash to torso). At the time of the report, DIARRHOEA (diarrhea) and RASH (rash to torso) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included TUMS
Patient had fever to Tmax of 103F on 05/05/2015. Low grade fevers for a total of 5 days. Measles like mildly erythematous maculopapular rash spreading over trunk, extremities and face starting 05/04/2015. Rash continues to spread. No other symptoms.
30 min, c/o slight numbness, tingling at injection site arm (L) vitals taken WNL. Sx resolved.
FLUZONE at 0930. At 1130 hrs throat was tightening and eyes got really dry. At 1300 throat worse & eyes started filling with "goopy" discharge at 1400 had hard time breathing & couldn't think.
Swelling of neck,shoulder, and arm; Swelling of neck,shoulder, and arm; Swelling of neck,shoulder, and arm; Temperature of 101; Body aches; Spasms in both legs; This is a spontaneous report from a contactable nurse (patient). A non-pregnant adult female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EN5519), intramuscular in right arm, on 28Jan2021 at 15:30 (03:30 PM), at a single dose, for COVID-19 immunization. The patient's medical history included allergies to shellfish and dyes or derivative. The patient's concomitant medication included losartan. The patient previously took the first dose of BNT162B2 (Lot Number: EL3246) on 07Jan2021 at 04:00 PM for COVID-19 immunization (intramuscular in right arm). Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The most recent COVID-19 vaccine was administered in a workplace clinic facility. On 29Jan2021 at 01:00 AM, the patient experienced swelling of neck, shoulder, and arm; temperature of 101; body aches; and spasms in both legs. The events were considered non-serious. No treatment was received for the adverse events. Since the vaccination, the patient has not been tested for COVID-19. The patient had not recovered from the events.
Rash shaped like band aid adhesive at injection site on 5/14/2021 after 1st injection days later. Nerve tingling sensations at the base of neck leading down to the right shoulder ten minutes after 2nd injection.
Within 20 minutes lips, face, left arm felt numb. Not long after that I had an asthma attack, hard time catching my breath, throat became itchy. This lasted for around 35 minutes.
Heart was placed into atrial fibrillation. Heart rate was 200BPM. Lost hearing and sense of balance. Profuse sweating and wheezing.
as pt left clinic area p/vax pt fainted & fell stricking a wall as fell;pt responded w/in 1-2min & was monitored by hlth dept & EMS for approx 15min;pt was d/c w/mom tp pvt MD for eval;c/o sl h/a & neck pain;dx by pp was vagal episode;
This case was reported by a physician to a sales representative and described the occurrence of hives in a 14 year old female subject who was vaccinated with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Boostrix) for prophylaxis. On Aug 26 2005 the subject received a dose of Boostrix. On Aug 27 2005, 1 day after vaccination with Boostrix, the subject experienced hives and rash all around the body. The subject was seen at a physicians office and was treated with diphenhydramine hydrochloride (Benadryl). On Aug 30 2005, the events were resolved. the physician considered the events to probably be related to vaccination with Boostrix.
Pt states developed burning itching eyes then wheezing, flushed hot face, throat felt like it was swelling.  Took a CLARITON dose and a physician gave script for ALBUTEROL.   Symptoms lasted approximately one hour.  (not witnessed by provider.  Pt did not seek ER evaluation)
large 10x6cm of redness w/ 4x5cm of firmness @ site of DTAP;2 other children who recv DTAP on same day had similar rxn;
Pt experienced body aches, lower joint swelling, headache and fever. Some of these symptoms persisted for 6 months.
Lack of menstruation. I was due for my period a few days after receiving my vaccine. It never came and still hasn?t. It has been almost a month.